Abstract
In silico classification of new compounds for certain properties is a useful tool to guide further experiments or compound selection. Interaction of new compounds with the efflux pump P-glycoprotein (P-gp) is an important drug property determining tissue distribution and the potential for drug-drug interactions. We present three datasets on substrate, inhibitor, and inducer activities for P-gp (n = 471) obtained from a literature search which we compared to an existing evaluation of the Prestwick Chemical Library with the calcein- AM assay (retrieved from PubMed). Additionally, we present decision tree models of these activities with predictive accuracies of 77.7 % (substrates), 86.9 % (inhibitors), and 90.3 % (inducers) using three algorithms (CHAID, CART, and C4.5). We also present decision tree models of the calcein-AM assay (79.9 %). Apart from a comprehensive dataset of P-gp interacting compounds, our study provides evidence of the efficacy of logD descriptors and of two algorithms not commonly used in pharmacological QSAR studies (CART and CHAID).
Keywords: P-glycoprotein, MDR1, Multidrug resistance, Calcein AM assay, QSAR, decision trees
Current Drug Metabolism
Title: Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein
Volume: 10 Issue: 4
Author(s): Felix Hammann, Heike Gutmann, Ursula Jecklin, Andreas Maunz, Christoph Helma and Juergen Drewe
Affiliation:
Keywords: P-glycoprotein, MDR1, Multidrug resistance, Calcein AM assay, QSAR, decision trees
Abstract: In silico classification of new compounds for certain properties is a useful tool to guide further experiments or compound selection. Interaction of new compounds with the efflux pump P-glycoprotein (P-gp) is an important drug property determining tissue distribution and the potential for drug-drug interactions. We present three datasets on substrate, inhibitor, and inducer activities for P-gp (n = 471) obtained from a literature search which we compared to an existing evaluation of the Prestwick Chemical Library with the calcein- AM assay (retrieved from PubMed). Additionally, we present decision tree models of these activities with predictive accuracies of 77.7 % (substrates), 86.9 % (inhibitors), and 90.3 % (inducers) using three algorithms (CHAID, CART, and C4.5). We also present decision tree models of the calcein-AM assay (79.9 %). Apart from a comprehensive dataset of P-gp interacting compounds, our study provides evidence of the efficacy of logD descriptors and of two algorithms not commonly used in pharmacological QSAR studies (CART and CHAID).
Export Options
About this article
Cite this article as:
Hammann Felix, Gutmann Heike, Jecklin Ursula, Maunz Andreas, Helma Christoph and Drewe Juergen, Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein, Current Drug Metabolism 2009; 10 (4) . https://dx.doi.org/10.2174/138920009788499021
DOI https://dx.doi.org/10.2174/138920009788499021 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: “Alkaloids in Nature: Synthesis, Isolation and Pharmacological Applications” Part 2)
Current Topics in Medicinal Chemistry Membrane Transporters in Physiological Barriers of Pharmacological Importance
Current Pharmaceutical Design Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Epigenetic MicroRNA Regulation of Multiple Chromatin Functions: A Perspective in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents
Mini-Reviews in Medicinal Chemistry New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design The Contrasting Roles of NKT Cells in Tumor Immunity
Current Molecular Medicine Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology Activatable Optical Probes for the Detection of Enzymes
Current Organic Synthesis Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design The Potential Targets and Mechanisms of a Carbazole and Pyrazole Containing Anticancer Compound
Current Cancer Drug Targets HLA-I Antigen Presentation and Tapasin Influence Immune Responses Against Malignant Brain Tumors-Considerations for Successful Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Anticancer Natural Products with Collateral Sensitivity: A Review
Mini-Reviews in Medicinal Chemistry Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers An Appraisal of Current Pharmacological Perspectives of Sesamol: A Review
Mini-Reviews in Medicinal Chemistry MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets